CA3180686A1 - Novel small molecules for targeted degradation of untargetable kras in cancer therapy - Google Patents
Novel small molecules for targeted degradation of untargetable kras in cancer therapy Download PDFInfo
- Publication number
- CA3180686A1 CA3180686A1 CA3180686A CA3180686A CA3180686A1 CA 3180686 A1 CA3180686 A1 CA 3180686A1 CA 3180686 A CA3180686 A CA 3180686A CA 3180686 A CA3180686 A CA 3180686A CA 3180686 A1 CA3180686 A1 CA 3180686A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- kras
- group bonded
- cancer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041023434 | 2020-06-04 | ||
| IN202041023434 | 2020-06-04 | ||
| PCT/IB2021/054591 WO2021245499A1 (en) | 2020-06-04 | 2021-05-26 | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180686A1 true CA3180686A1 (en) | 2021-12-09 |
Family
ID=78830675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180686A Pending CA3180686A1 (en) | 2020-06-04 | 2021-05-26 | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230202981A1 (https=) |
| EP (1) | EP4161511B1 (https=) |
| JP (1) | JP7789016B2 (https=) |
| KR (1) | KR20230019937A (https=) |
| CN (2) | CN115768427B (https=) |
| AU (1) | AU2021284517A1 (https=) |
| BR (1) | BR112022024300A2 (https=) |
| CA (1) | CA3180686A1 (https=) |
| IL (1) | IL298672A (https=) |
| MX (1) | MX2022015253A (https=) |
| WO (1) | WO2021245499A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2025083563A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Effective therapeutic small-molecule inhibitors for metastatic cancer |
| WO2025083561A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel lead small molecule inhibitors on undruggable target towards anticancer activity |
| WO2025083564A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small molecule degrader as a potential anticancer |
| WO2025083568A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule protein kinase inhibitors for implications in cancer treatment |
| WO2025083570A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule agents in overcoming tumor regression in cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA12274A (en) * | 2000-05-22 | 2006-05-09 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors. |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| HUP0402106A3 (en) * | 2001-11-01 | 2009-07-28 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
| US20190284149A1 (en) * | 2014-09-12 | 2019-09-19 | Ariagen, Inc. | Aryl hydrocarbon receptor modulator |
| CN106317055A (zh) * | 2015-07-02 | 2017-01-11 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| WO2018140513A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| CN110885332B (zh) * | 2019-12-06 | 2022-03-18 | 中国人民解放军第二军医大学 | 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用 |
-
2021
- 2021-05-26 US US18/008,332 patent/US20230202981A1/en active Pending
- 2021-05-26 BR BR112022024300A patent/BR112022024300A2/pt unknown
- 2021-05-26 CA CA3180686A patent/CA3180686A1/en active Pending
- 2021-05-26 IL IL298672A patent/IL298672A/en unknown
- 2021-05-26 MX MX2022015253A patent/MX2022015253A/es unknown
- 2021-05-26 KR KR1020237000112A patent/KR20230019937A/ko active Pending
- 2021-05-26 CN CN202180049321.9A patent/CN115768427B/zh active Active
- 2021-05-26 CN CN202510275737.2A patent/CN120208921A/zh active Pending
- 2021-05-26 JP JP2022574452A patent/JP7789016B2/ja active Active
- 2021-05-26 WO PCT/IB2021/054591 patent/WO2021245499A1/en not_active Ceased
- 2021-05-26 AU AU2021284517A patent/AU2021284517A1/en active Pending
- 2021-05-26 EP EP21817859.8A patent/EP4161511B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4161511A1 (en) | 2023-04-12 |
| JP7789016B2 (ja) | 2025-12-19 |
| KR20230019937A (ko) | 2023-02-09 |
| MX2022015253A (es) | 2023-03-14 |
| IL298672A (en) | 2023-01-01 |
| BR112022024300A2 (pt) | 2023-01-24 |
| TW202210465A (zh) | 2022-03-16 |
| CN115768427B (zh) | 2025-03-28 |
| WO2021245499A1 (en) | 2021-12-09 |
| CN115768427A (zh) | 2023-03-07 |
| EP4161511B1 (en) | 2026-04-29 |
| AU2021284517A1 (en) | 2023-01-05 |
| JP2023529354A (ja) | 2023-07-10 |
| EP4161511A4 (en) | 2024-07-17 |
| CN120208921A (zh) | 2025-06-27 |
| US20230202981A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4161511B1 (en) | Novel small molecules for targeted degradation of untargetable kras in cancer therapy | |
| WO2022135346A1 (en) | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers | |
| EP3733187B1 (en) | Chiral diaryl macrocycle and use thereof in the treatment of cancer | |
| JP6193268B2 (ja) | Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 | |
| JP6911019B2 (ja) | Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬 | |
| Foran et al. | A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis | |
| CN110325191A (zh) | 以较少的副作用治疗egfr-驱动的癌症 | |
| JP2014533284A5 (https=) | ||
| KR20140096375A (ko) | 항종양제의 효과 증강제 | |
| CN107666906A (zh) | 用于治疗癌症的方法 | |
| JP2025519119A (ja) | Ｍｅｋ阻害剤及びその使用 | |
| CA2837042A1 (en) | A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | |
| US11884685B2 (en) | Rhenium complexes and methods of use for treating cancer | |
| CN107708700A (zh) | 用于治疗癌症的方法 | |
| JP6373252B2 (ja) | オーロラキナーゼ阻害薬を使用する癌の治療方法 | |
| TWI916370B (zh) | 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子 | |
| RU2839932C1 (ru) | Новые малые молекулы для целенаправленного расщепления не поддающегося целенаправленному воздействию kras в терапии рака | |
| AU2016296997B2 (en) | Chlorobenzene substituted azaaryl compounds | |
| CN111718328A (zh) | 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途 | |
| WO2015153866A1 (en) | Cancer therapy with ganetespib and an egfr inhibitor | |
| Sharma et al. | New and potential therapies for the treatment of Breast Cancer: An update for oncologists | |
| WO2025083565A1 (en) | Phenotype and genotype target-based small molecule inhibitors in cancers | |
| WO2026006342A1 (en) | Direct-binding dual inhibitors of hypoxia-inducible factor 1 (hif-1) and hif-2 | |
| GB2643430A (en) | Nuclear transport inhibitors for anti-cancer combination therapy | |
| TW201605449A (zh) | 馬賽替尼治療結腸直腸癌的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241119 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250514 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250514 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250519 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250519 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250801 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250801 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250801 |